Percheron Therapeutics (ASX:PER) advanced its phase 2b trial investigating the use of avicursen (ATL1102) in patients with Duchenne muscular dystrophy, according to a Monday filing with the Australian bourse.
All 48 patients from the randomized, placebo-controlled trial completed their 25th-week visit, with results expected by the week starting Dec. 16, the filing said. The trial's 12-month study data is anticipated for mid-2025.
The company's shares were down almost 3% in recent Monday trade.
Price (AUD): $0.07, Change: $-0.002, Percent Change: -2.70%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。